J, Lundgren et al. A neutralizing monoclonal antibody for hospitalized patients with COVID-19. New England Journal of Medicine. DOI: 10.1056/NEJMoa2033130 (2020).

B. F. Haynes et al., Prospects for a safe COVID-19 vaccine, Sci. Transl. Med. 10.1126/scitranslmed.abe0948 (2020). 

Grobler, J.A, Anderson, A.S, Fernandes, P., Diamond, M.S, Colvis, C.M, Menetski, J.P, Alvarez, R.M, Young, J.A., Carter, K.L, on behalf of the ACTIV Preclinical Working Group, Accelerated preclinical paths to support rapid development of COVID-19 therapeutics, Cell Host and Microbe (2020), doi:

Hewitt, J.A., Lutz, C., Florence, W.C., Pitt, M.L.M., Rao, S., Rappaport, J., Haigwood, N.L., on behalf of theACTIV Preclinical Working Group, ACTIVating Resources for the COVID-19 Pandemic: In vivo Models for Vaccines and Therapeutics, Cell Host and Microbe (2020), doi: 

Deming ME, Michael NL, Robb M, Cohen MS, Neuzil KM. Accelerating Development of SARS-CoV-2 Vaccines - The Role for Controlled Human Infection Models [published online ahead of print, 2020 Jul 1]. N Engl J Med. 2020;10.1056/NEJMp2020076. doi:10.1056/NEJMp2020076

Collins FS, Stoffels P. Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): An Unprecedented Partnership for Unprecedented Times [published online ahead of print, 2020 May 18]. JAMA. 2020;10.1001/jama.2020.8920. doi:10.1001/jama.2020.8920

Corey L, Mascola JR, Fauci AS, Collins FS. A strategic approach to COVID-19 vaccine R&D. Science. 2020;368(6494):948-950. doi:10.1126/science.abc5312

This page last reviewed on December 23, 2020